Total Payments
$231,930
2024 Payments
$52,203
Companies
9
Transactions
166
Medicare Patients
281
Medicare Billing
$59,955
Payment Breakdown by Category
Other$155,283 (67.0%)
Consulting$53,917 (23.2%)
Travel$17,338 (7.5%)
Food & Beverage$3,572 (1.5%)
Research$1,820 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $142,597 | 44 | 61.5% |
| Consulting Fee | $53,917 | 15 | 23.2% |
| Travel and Lodging | $17,338 | 51 | 7.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $6,786 | 2 | 2.9% |
| Honoraria | $5,900 | 3 | 2.5% |
| Food and Beverage | $3,572 | 50 | 1.5% |
| Unspecified | $1,820 | 1 | 0.8% |
Payments by Type
General
$230,110
165 transactions
Research
$1,820
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $66,926 | 64 | $0 (2024) |
| PharmaEssentia USA Corporation | $55,649 | 37 | $0 (2024) |
| GlaxoSmithKline, LLC. | $39,007 | 20 | $0 (2024) |
| Celgene Corporation | $38,444 | 22 | $0 (2023) |
| CTI BioPharma Corp. | $17,564 | 11 | $0 (2023) |
| SOBI, INC | $11,756 | 8 | $0 (2024) |
| PFIZER INC. | $1,820 | 1 | $0 (2022) |
| Karyopharm Therapeutics Inc. | $730.48 | 2 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $33.96 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $52,203 | 32 | GlaxoSmithKline, LLC. ($17,173) |
| 2023 | $58,573 | 36 | PharmaEssentia USA Corporation ($28,226) |
| 2022 | $40,417 | 29 | Incyte Corporation ($14,222) |
| 2021 | $16,272 | 10 | Incyte Corporation ($9,226) |
| 2020 | $17,263 | 8 | Celgene Corporation ($17,263) |
| 2019 | $19,293 | 15 | Celgene Corporation ($13,048) |
| 2018 | $12,252 | 14 | Incyte Corporation ($12,252) |
| 2017 | $15,656 | 22 | Incyte Corporation ($15,622) |
All Payment Transactions
166 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,666.00 | General |
| Category: Oncology | ||||||
| 11/15/2024 | SOBI, INC | VONJO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,625.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/15/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $122.11 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/13/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Travel and Lodging | In-kind items and services | $1,216.71 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $119.76 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $130.48 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: Oncology | ||||||
| 10/07/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,165.00 | General |
| Category: Oncology | ||||||
| 10/02/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Travel and Lodging | Cash or cash equivalent | $89.78 | General |
| Category: Oncology | ||||||
| 09/19/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $116.37 | General |
| Category: Oncology | ||||||
| 09/11/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,800.00 | General |
| Category: ONCOLOGY | ||||||
| 09/09/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,082.50 | General |
| Category: Oncology | ||||||
| 08/29/2024 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $8,220.00 | General |
| 08/26/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $195.64 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 08/26/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $88.28 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 08/22/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $913.04 | General |
| 08/21/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $65.16 | General |
| 08/21/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $40.45 | General |
| 08/21/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $31.46 | General |
| 08/21/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $4.83 | General |
| 08/20/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $29.96 | General |
| 08/13/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ONCOLOGY | ||||||
| 07/31/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Consulting Fee | Cash or cash equivalent | $4,998.00 | General |
| Category: Oncology | ||||||
| 07/08/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| 06/20/2024 | SOBI, INC | VONJO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,625.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| BOSUTINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,820 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 75 | 119 | $54,866 | $9,758 |
| 2022 | 3 | 84 | 237 | $116,262 | $21,640 |
| 2021 | 2 | 57 | 191 | $93,404 | $18,611 |
| 2020 | 1 | 65 | 140 | $53,718 | $9,946 |
Total Patients
281
Total Services
687
Medicare Billing
$59,955
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 48 | 80 | $32,480 | $5,869 | 18.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 27 | 39 | $22,386 | $3,888 | 17.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 18 | 113 | $51,302 | $9,733 | 19.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 43 | 87 | $49,938 | $9,325 | 18.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 23 | 37 | $15,022 | $2,583 | 17.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 42 | 106 | $54,814 | $11,020 | 20.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 15 | 85 | $38,590 | $7,591 | 19.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 40 | 99 | $33,877 | $5,910 | 17.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 25 | 41 | $19,841 | $4,036 | 20.3% |
About Dr. Angela Fleischman, MD
Dr. Angela Fleischman, MD is a Medical Oncology healthcare provider based in Orange, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/20/2007. The National Provider Identifier (NPI) number assigned to this provider is 1922216175.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Angela Fleischman, MD has received a total of $231,930 in payments from pharmaceutical and medical device companies, with $52,203 received in 2024. These payments were reported across 166 transactions from 9 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($142,597).
As a Medicare-enrolled provider, Fleischman has provided services to 281 Medicare beneficiaries, totaling 687 services with total Medicare billing of $59,955. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Orange, CA
- Active Since 05/20/2007
- Last Updated 06/06/2025
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1922216175
Products in Payments
- BESREMI (Drug) $55,649
- JAKAFI (Drug) $35,809
- OJJAARA (Drug) $27,936
- INREBIC (Drug) $24,309
- Vonjo (Drug) $17,564
- VONJO (Drug) $11,756
- BOSULIF (Drug) $1,820
- Inrebic (Drug) $1,500
- XPOVIO (Drug) $730.48
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Orange
Dr. Farshid Dayyani, M.d., Ph.d, M.D., PH.D
Medical Oncology — Payments: $1.0M
Medical Oncology $1.0M
Susan O'brien, M.d, M.D
Medical Oncology — Payments: $572,208
Medical Oncology $572,208
Dr. Sayeh Lavasani, Md, MD
Medical Oncology — Payments: $140,119
Medical Oncology $140,119
Victoria Villaflor, M.d, M.D
Medical Oncology — Payments: $108,593
Medical Oncology $108,593
Dr. Matko Kalac, M.d., Ph.d, M.D., PH.D
Medical Oncology — Payments: $62,363
Medical Oncology $62,363
Ms. Mihaela Cristea, Md, MD
Medical Oncology — Payments: $25,039
Medical Oncology $25,039